Inclusion Criteria:

• * Patients 18 years of age or older with unilateral primary choroidal melanoma
• * Patients with diagnosis of small or medium ocular melanomas amenable to plaque brachytherapy (as determined by treating ocular oncologist). Typically this would include tumors with apical height ≤10mm and basal diameter ≤16mm (small and medium tumors per COMS (Collaborative Ocular Melanoma Study)
• * Patients with no clinical evidence of metastatic disease as confirmed by negative staging imaging (CT, MRI, and/or ultrasound)
• * Patients with best-corrected visual acuity in the fellow eye of 20/200 or better
• * Patients must be treated with IsoAid Eye Physics eye plaques

Exclusion Criteria:

• * Patients whose tumors are circumferential around the optic disc and cannot be adequately covered by the prescription dose are ineligible.
• * Similarly, patients with extrascleral tumor extension detected during echography or clinical exam, diffuse, ring or multifocal tumors that cannot be encompassed in a single episcleral plaque or tumors judged to be predominantly ciliary body or iris melanoma will be considered ineligible
• * Previous treatment for ocular melanoma in either eye or treatment of any condition secondary to the tumor are ineligible.
• * Patients with a history of other primary or metastatic cancers are not eligible, except for non-melanotic skin cancers
• * Patients with extraocular disease